924 material Form 8-K filings that 737 companies we cover made with the SEC in January 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Lafayette Digital Acquisition Corp. I, a Cayman Islands blank check company, closed its initial public offering on January 12, 2026, selling 28,750,000 units at $10.00 each for gross proceeds of $287.5 million, including the full exercise of the underwriters' over-allotment option. The filing says the net proceeds, including $10,062,500 in deferred underwriting commissions, were placed in a trust account for public shareholders, and the company intends to use the proceeds to pursue a business combination with one or more businesses.
IPO closed January 12, 2026: 28,750,000 units at $10.00 per unit, including 3,750,000 over-allotment units, for gross proceeds of $287,500,000.
Each unit includes one Class A ordinary share and one-fourth of one redeemable warrant exercisable at $11.50 per share.
Private placement of 760,000 units for $7,600,000 to the Sponsor (435,000 units) and BTIG, LLC (325,000 units).
Jason Glazer and Robert Cusack were appointed to the board on January 8, 2026; the amended and restated articles were adopted in connection with the IPO.
Amphastar entered into an exclusive license agreement with Nanjing Hanxin Pharmaceutical Technology on January 6, 2026, for AMP-110, a fully synthetic corticotropin compound in early-phase human clinical development, covering the United States and Canada. Hanxin is controlled by family members of Amphastar's CEO and Chairman, so the agreement and two related amendments are related party transactions, and the company says the amendments are not expected to be material.
Amphastar made a $2 million upfront payment to Hanxin, with up to $14 million in development milestones and up to $75 million in sales milestones.
Royalties payable by Amphastar to Hanxin are capped at $7.5 million per calendar year and $60 million in total accumulated.
Dr. Jack Zhang and Dr. Mary Luo and certain family members own a majority of Hanxin; the Audit Committee approved the distribution and manufacturing amendments.
The Distribution and Manufacturing Amendments expand territories; their value is not determinable until sales occur in the expanded regions.
Shake Shack released preliminary unaudited results for the fourth quarter and fiscal 2025, showing total revenue of $400.5 million for the quarter and $1.45 billion for the year, with same-Shack sales up 2.1% and 2.3%. The company said the last six weeks of the quarter did not meet its expectations because of inclement weather, and it issued initial fiscal 2026 guidance of $1.6 billion to $1.7 billion in total revenue and $237.0 million to $245.0 million in adjusted EBITDA. The figures remain subject to audit and the Form 10-K.
4Q25 total revenue of $400.5 million; FY25 total revenue of $1.45 billion
Same-Shack sales up 2.1% in 4Q25 and 2.3% in FY25; last six weeks of 4Q25 missed expectations due to weather
FY26 guidance: net income of $50.0 million to $60.0 million and adjusted EBITDA of $237.0 million to $245.0 million
45 Company-operated Shacks opened in FY25; 55 to 60 planned for 2026
Inspire Medical Systems reported preliminary, unaudited revenue for the fourth quarter and full year 2025, with full-year revenue up about 14% from 2024, and gave initial 2026 revenue guidance of $1,003 million to $1,013 million, a 10% to 11% increase. The company said final results may differ and the audit is not complete. It also named Matthew Osberg as Chief Financial Officer, starting January 19, 2026, succeeding interim CFO Richard Buchholz.
Q4 2025 revenue preliminarily estimated at $268.9 million to $269.1 million, about 12% higher than Q4 2024
Full-year 2025 revenue preliminarily estimated at $911.8 million to $912.0 million, about 14% higher than 2024
2026 revenue guidance of $1,003 million to $1,013 million, reaffirmed from the outlook given on the third-quarter 2025 call; excludes any increase from reimbursement
Matthew Osberg's start date is January 19, 2026; his CFO appointment is effective after the 2025 Form 10-K is filed, with a $650,000 base salary and a $600,000 sign-on bonus
Arrowhead Pharmaceuticals issued $700 million of 0.00% convertible senior notes due January 15, 2032, including $75 million from the underwriters' full exercise of their over-allotment option. The company also spent approximately $47.9 million on capped call transactions, which are expected to reduce potential dilution from future conversions of the notes.
Notes issued January 12, 2026: $700 million principal, 0.00% interest rate, maturing January 15, 2032
Initial conversion price of approximately $87.07 per share; the company may settle conversions in cash, shares or a combination
Capped call transactions cost approximately $47.9 million, with a cap price of approximately $119.33 per share
Company may redeem notes on or after January 16, 2029 if the stock exceeds 130% of the conversion price under specified conditions
BioMarin said at the J.P. Morgan Healthcare Conference that preliminary 2025 total revenue was about $3.2 billion, within its prior guidance, and that VOXZOGO sales were about $920 million. The company also expects a fourth-quarter 2025 Roctavian asset write-down of $230 million to $260 million, which reduces non-GAAP diluted EPS by $0.60 to $0.64 per share, while its non-GAAP EPS guidance excluding the write-down is unchanged.
Preliminary 2025 total revenue of about $3.2 billion, against prior guidance of $3.15 billion to $3.2 billion
VOXZOGO 2025 revenue of about $920 million, against prior guidance of $900 million to $935 million
Roctavian write-down of $230 million to $260 million in Q4 2025, with $120 million to $125 million reducing non-GAAP diluted EPS by $0.60 to $0.64 per share
Full fourth-quarter and 2025 results expected in February 2026; figures are unaudited and preliminary
Crown Castle said DISH Wireless defaulted on its payment obligations and that it has terminated its wireless infrastructure agreement with DISH, seeking to recover more than $3.5 billion in remaining payments. The company said it does not expect the termination to affect its full-year 2025 results, but the filing does not describe how the dispute will be resolved or how much cash will be collected.
DISH Wireless defaulted on payment obligations; Crown Castle delivered a notice of default and termination on January 12, 2026.
Crown Castle seeks to recover more than $3.5 billion in remaining payments owed under the agreement.
Crown Castle does not anticipate the termination to affect its full-year 2025 financial results.
T-Mobile USA, a wholly-owned subsidiary of T-Mobile US, closed an underwritten public offering of $1.15 billion of 5.000% senior notes due 2036 and $850 million of 5.850% senior notes due 2056 on January 12, 2026. Net proceeds are expected to refinance existing indebtedness on an ongoing basis or for general corporate purposes, and the notes are guaranteed on a senior unsecured basis by the parent and certain subsidiaries.
2036 Notes: $1.15 billion principal at a 5.000% coupon
2056 Notes: $850 million principal at a 5.850% coupon
Offering closed January 12, 2026, under an underwriting agreement dated January 7, 2026
Proceeds expected for refinancing existing debt or general corporate purposes
Artisan Partners reported preliminary assets under management of $179.9 billion as of December 31, 2025, in a press release filed with the 8-K. The filing also says the board added Clarence Kane Brenan as a director on January 9, 2026, expanding it from eight to nine members, and that a subsidiary closed its acquisition of Grandview Property Partners, LLC on January 2, 2026.
Total firm AUM was $179.9 billion as of December 31, 2025, including $87.8 billion in Artisan Funds and Artisan Global Funds and $92.1 billion in separate accounts and other AUM.
December month-end AUM includes the impact of approximately $640 million of Artisan Funds distributions that were not reinvested.
Clarence Kane Brenan, former CEO of TIFF Investment Management, was appointed to the board on January 9, 2026 and to the Compensation Committee.
A subsidiary closed its previously announced acquisition of 100% of the equity of Grandview Property Partners, LLC on January 2, 2026.
Chipotle said two executives, Chief Legal Officer Roger Theodoredis and President and Chief Brand Officer Chris Brandt, have transitioned out of their executive roles effective January 12, 2026, and will stay on in advisory roles for a limited period. Chief Human Resources Officer Ilene Eskenazi takes on the combined chief legal and human resources role, and Stephanie Perdue is interim Chief Marketing Officer while the company searches for a permanent CMO. The company also reaffirmed its full-year 2025 guidance issued in October, which keeps its prior financial outlook unchanged.
Ilene Eskenazi appointed Chief Legal and Human Resources Officer, effective immediately, succeeding Roger Theodoredis
Stephanie Perdue, Vice President of Brand Marketing, named interim Chief Marketing Officer, succeeding Chris Brandt
Company reaffirmed full-year 2025 financial guidance issued in October 2025
Fourth quarter and fiscal year 2025 earnings call scheduled for February 3, 2026
Option Care Health said it expects 2025 net revenue of $5.645 billion to $5.655 billion and adjusted diluted EPS of $1.72 to $1.76, both preliminary and unaudited, and gave preliminary 2026 guidance of $5.8 billion to $6.0 billion in net revenue and $1.82 to $1.92 in adjusted diluted EPS. The company also raised its 2025 share repurchase authorization from $500 million to $1 billion, which matters to shareholders because it expands the room for buybacks.
FY2025 preliminary net revenue $5.645 billion to $5.655 billion; adjusted diluted EPS $1.72 to $1.76; GAAP diluted EPS $1.27 to $1.29
FY2026 preliminary guidance: net revenue $5.8 billion to $6.0 billion; adjusted diluted EPS $1.82 to $1.92; adjusted EBITDA $480 million to $505 million
Board approved on January 9, 2026 to raise the 2025 share repurchase authorization from $500 million to $1 billion; $307 million repurchased in full-year 2025
FY2025 cash flow from operations below $320 million; the company says Stelara and Stelara biosimilars will be a 2026 headwind of $25 million to $35 million in gross profit
Regions Financial said Chief Financial Officer David Turner will retire effective March 31, 2026, and Anil Chadha, currently Controller and head of Corporate Finance, will succeed him as Senior Executive Vice President, Chief Financial Officer. A CFO change is a significant leadership transition, and the filing says the two will work together through March to ensure a smooth handoff, while Chadha's compensation terms have not yet been disclosed.
David J. Turner, Jr. retires as CFO effective March 31, 2026, after about 40 years in auditing and finance, including 20 years at the bank
Anil D. Chadha, 47, becomes CFO upon Turner's retirement; he has been Controller since December 2021 and head of Corporate Finance since December 2023
Regions says material compensation terms for both executives will be disclosed once approved
Exelixis said preliminary, unaudited fiscal 2025 net product revenue was about $2.123 billion and total revenue was about $2.320 billion. It also gave fiscal 2026 net product revenue guidance of $2.325 billion to $2.425 billion, which excludes any revenue from a potential zanzalintinib launch. The audit is ongoing, and final results are due February 10, 2026, so the figures could change.
Preliminary fiscal 2025 total revenues of about $2.320 billion and net product revenues of about $2.123 billion
Fiscal 2026 guidance: total revenues of $2.525 billion to $2.625 billion and net product revenues of $2.325 billion to $2.425 billion
Audited fiscal 2025 results are scheduled for release on February 10, 2026
An October 2025 buyback authorizes up to an additional $750 million of stock repurchases before December 31, 2026
ANI Pharmaceuticals said preliminary, unaudited 2025 results are within or above its prior guidance, with Cortrophin Gel net revenues up 76% for the year. It also issued 2026 guidance calling for total net revenues of $1.055 billion to $1.115 billion and adjusted non-GAAP diluted EPS of $8.83 to $9.34, and said the 2025 figures may change materially before the audit is complete.
Preliminary 2025 total net revenues are expected to be within or above $854 million to $873 million, adjusted non-GAAP EBITDA $221 million to $228 million, and adjusted non-GAAP diluted EPS $7.37 to $7.64.
Cortrophin Gel net revenues were approximately $347.8 million for 2025, up 76% year over year, and approximately $111.4 million for the fourth quarter, up 88%.
2026 guidance: total net revenues $1.055 billion to $1.115 billion, adjusted non-GAAP EBITDA $275 million to $290 million, and adjusted non-GAAP diluted EPS $8.83 to $9.34.
The company had approximately $285 million in unrestricted cash and cash equivalents as of December 31, 2025; the company plans to report full 2025 results in late February.
Pool Corporation announced that Kenneth G. St. Romain, Senior Vice President, will retire in 2026 and will stay in his role until later in the year to assist with the transition. The company also said John B. Watwood joined as Executive Vice President effective January 12, 2026, leading North American swimming pool operations and overseeing digital and technology initiatives. The filing contains no financial results, so the change is administrative in nature for shareholders.
Kenneth G. St. Romain, Senior Vice President, will retire in 2026 and has not set a specific retirement date.
John B. Watwood joined as Executive Vice President effective January 12, 2026, reporting to CEO Peter D. Arvan.
Watwood will lead North American swimming pool operations and oversee digital and technology initiatives.
Watwood previously held management roles at Motion Industries, Inc. since 2008, most recently as Senior Vice President of Sales and Operations for the United States and Canada.
CAVA Group announced that Douglas W. Thompson will become its Chief Operations Officer effective March 2, 2026, overseeing restaurant operations and field teams and reporting to CEO Brett Schulman. The filing sets out his compensation, including a $550,000 base salary, a target cash bonus of 75% of base salary, and a $200,000 relocation and sign-on bonus, which adds a new operations executive and the associated pay terms for shareholders to note.
Thompson, 62, becomes Chief Operations Officer effective March 2, 2026 and reports directly to CEO Brett Schulman.
Offer letter provides a $550,000 annual base salary and a target cash bonus of 75% of base salary.
Equity award with approximate grant date value of $1,200,000 expected from fiscal 2027, plus a one-time restricted stock unit grant of approximately $500,000 and a $200,000 sign-on bonus.
Thompson was CEO of Tumble 22 Texas Chicken Joint from October 2022 and served as COO of Texas Roadhouse from August 2018 to December 2021.
NETSTREIT issued a business update for the fourth quarter and full year 2025 and initiated 2026 adjusted funds from operations (AFFO) per share guidance of $1.35 to $1.39. The company reaffirmed its 2025 AFFO per share guidance of $1.30 to $1.31 and reported record gross investment activity of $657.1 million at a 7.5% blended cash yield for 2025. The update did not include revenue, net income or GAAP earnings per share figures.
2026 AFFO per share guidance: $1.35 to $1.39; 2026 net investment activity expected at $350.0 million to $450.0 million
2025 AFFO per share guidance of $1.30 to $1.31 reaffirmed; 2025 gross investments totaled $657.1 million, a record per the release
Total liquidity of $1,037.4 million as of December 31, 2025; Fitch assigned an investment grade rating of BBB- in December 2025
Guidance includes $0.015 to $0.03 per share of estimated dilution from outstanding forward equity
Tanger's operating partnership issued $250 million of 2.375% exchangeable senior notes due January 15, 2031, including a $30 million option exercise. Net proceeds were about $243 million, which the company plans to use to repay a $350 million 3.125% note maturing September 1, 2026, repay credit line debt, and for general corporate purposes. The notes can be exchanged for Tanger common shares at an initial price of about $41.55, a 22.5% premium over the January 7, 2026 closing price of $33.92.
Notes: $250 million principal at 2.375% interest, maturing January 15, 2031, including $30 million from full exercise of the initial purchasers' option.
Net proceeds of about $243 million; about $20 million used to repurchase roughly 0.6 million common shares at $33.92 and about $9 million used for capped call transactions.
Planned use: repay the $350 million 3.125% senior notes due September 1, 2026, and outstanding unsecured line of credit debt.
Initial exchange price of about $41.55 per share; the notes are guaranteed by Tanger Inc. on a senior unsecured basis.
Alexandria Real Estate amended the 2025 long-term incentive grant for Executive Chairman Joel S. Marcus, so 100% of the grant now vests only on corporate performance criteria, with no time-based vesting. The filing says the target value stays at $3.6 million, while the maximum value rises to $5.4 million from $4.5 million under the prior terms. The company also elected John Hart Cole as Co-President and Co-Regional Market Director for Seattle, effective January 1, 2026.
Marcus's 2025 LTI grant, made January 9, 2026, keeps a $3.6 million target value, now fully performance-based.
Maximum value of the 2025 grant rises to $5.4 million, or 150% of the target, from a prior combined maximum of $4.5 million.
The amendment applies only to the 2025 grant and not to later grants or other awards to Marcus.
John Hart Cole was elected Co-President effective January 1, 2026; his only contemplated pay change is a base salary increase, with no amount disclosed.
Flanigan's Enterprises announced a broad leadership reshuffle, with James G. Flanigan II stepping down as President and Chairman, and Jeffrey D. Kastner stepping down as CFO to become Chairman and Chief Legal Officer. Allison Govoni becomes CFO and Peter Bruce becomes COO, both internal promotions, which shareholders may view as a significant change in top management.
James G. Flanigan II resigned as President and Chairman effective January 8, 2026, and remains CEO and a Board member
Jeffrey D. Kastner resigned as CFO effective January 8, 2026, and was named Chief Legal Officer and Chairman of the Board
Christopher O'Neil was named President effective January 8, 2026, with an annual base salary of $464,000
Allison Govoni named CFO effective January 8, 2026, at $222,000 annual base salary; Peter Bruce named COO at $272,000
Sarepta gave preliminary, unaudited fourth-quarter and full-year 2025 results at the J.P. Morgan Healthcare Conference, reporting $369.6 million in fourth-quarter net product revenue and $1.86 billion for the year. The company reconfirmed a yearly ELEVIDYS sales floor of $500.0 million but said it will not provide more detailed 2026 guidance until it evaluates its initiatives. Final results are due in late February 2026 and may differ materially from these figures.
Full-year 2025 total net product revenue of $1.86 billion; fourth quarter $369.6 million
ELEVIDYS fourth-quarter net product revenue of $110.4 million, affected by a severe flu season and rescheduling of 6 patient infusions into 2026
PMO net product revenue of $259.2 million in the fourth quarter and $965.6 million for the full year
Year-end 2025 cash, cash equivalents, restricted cash and investments of approximately $953.8 million; final results expected in late February 2026
On January 12, 2026, Bruker said during a J.P. Morgan Healthcare Conference presentation that preliminary fourth-quarter 2025 revenue is expected to be between $965 million and $970 million. It also outlined a preliminary 2026 outlook calling for flat to low-single-digit organic revenue growth, organic operating margin expansion of 250 to 300 basis points, and double-digit non-GAAP earnings per share growth, each compared with 2025. The fourth-quarter and full-year figures are unaudited and not yet finalized, and final results may differ materially.
Preliminary Q4 2025 revenue expected between $965 million and $970 million
Fourth-quarter 2025 Bruker Scientific Instruments book-to-bill ratio above 1.0
2026 outlook: organic revenue growth flat to up low-single digits versus 2025
2026 outlook: non-GAAP organic operating margin to expand 250 to 300 basis points and non-GAAP EPS to grow in double digits
PTC Therapeutics said preliminary, unaudited 2025 total product and royalty revenue was about $823.4 million, which it describes as exceeding its guidance. The company also guided to 2026 total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue, and to GAAP R&D and SG&A expense of $775 million to $815 million. Final 2025 results remain subject to the year-end audit.
Unaudited 2025 total product and royalty revenue of about $823.4 million; unaudited total product revenue of about $587.8 million
Sephience unaudited Q4 2025 net revenue of about $92.5 million, including $81.6 million in the US and $10.9 million ex-US
2026 guidance: total product revenue of $700 million to $800 million, excluding Evrysdi royalty and collaboration revenue
2026 GAAP R&D and SG&A expense guidance of $775 million to $815 million, or $680 million to $720 million excluding about $95 million of non-cash stock-based compensation
Danaher estimated that fourth-quarter 2025 revenue rose in the mid-single digit percent range year over year, with non-GAAP core revenue growth toward the high end of its low-single digit guidance. It also expects full-year 2025 non-GAAP adjusted diluted EPS toward the high end of its $7.70 to $7.80 guidance range, which suggests results came in at or above the company's prior outlook. These figures are preliminary estimates ahead of the January 28, 2026 earnings call.
Q4 2025 estimated revenue growth: mid-single digit percent range year over year
Q4 2025 non-GAAP core revenue growth expected toward the high end of low-single digit guidance
FY 2025 non-GAAP adjusted diluted EPS expected toward the high end of the $7.70 to $7.80 range
CEO Rainer M. Blair to comment at J.P. Morgan Healthcare Conference on January 13, 2026; earnings call January 28, 2026
Concentra published a presentation for the J.P. Morgan Healthcare Conference, to be given January 14, 2026, with preliminary, unaudited Q4 2025 operational metrics. The filing shows early visits-per-day growth but no revenue, profit or earnings per share figures for the quarter, which the company says will come in late January.
Early look shows Q4 2025 visits per day up year over year at +3.4%, +9.1%, +2.3% and +9.4% across total company (excluding Nova), workers' compensation and employer services.
Concentra repurchased about 1.1 million shares in Q4 2025.
Late January: Q4 and FY 2025 flash results and 2026 guidance; regularly scheduled Q4 earnings call in late February.
Presentation lists FY 2025 guidance of $2.145 billion to $2.160 billion in revenue and $425 million to $430 million in Adjusted EBITDA.
Jazz Pharmaceuticals said in a January 12, 2026 filing that it expects to meet its previously announced total revenue guidance range for the year ended December 31, 2025. The company will present the update at the J.P. Morgan Healthcare Conference on January 13, 2026, and says the 2025 results have not been finalized and actual results may differ.
Expects to meet the 2025 total revenue guidance range provided on November 5, 2025
Presentation slides show Xywav and Epidiolex each with $1B+ in 2025 sales, and Modeyso with nearly $50 million in 2025 revenue
Figures are unaudited; the company states 2025 financial results have not been finalized and actual results may differ
Update to be presented January 13, 2026 at the J.P. Morgan Healthcare Conference in San Francisco
Amphenol completed its acquisition of CommScope's Connectivity and Cable Solutions (CCS) business on January 9, 2026, for approximately $10.5 billion in cash, subject to customary post-closing adjustments. Amphenol expects the business to generate approximately $4.1 billion in full-year 2026 sales and to add approximately $0.15 to 2026 diluted earnings per share, excluding acquisition-related expenses. Financial statements and pro forma information for the business will be filed later by amendment.
Acquisition closed January 9, 2026, for approximately $10.5 billion in cash, subject to customary post-closing adjustments
Expected full-year 2026 sales for the CCS business of approximately $4.1 billion
Expected accretion of approximately $0.15 to 2026 diluted EPS, excluding acquisition-related expenses
CCS business will join the Communications Solutions Segment, with approximately 20,000 employees
Allegiant agreed on January 11, 2026 to merge with Sun Country Airlines, with Sun Country becoming a wholly owned subsidiary. Sun Country holders would receive $4.10 in cash and 0.1557 Allegiant shares per share, and the companies say the deal values Sun Country at about $1.5 billion including $0.4 billion of net debt. The deal requires stockholder, regulatory and other approvals and is expected to close in the second half of 2026, with Allegiant shareholders owning about 67% of the combined company.
Sun Country holders would receive $4.10 in cash plus 0.1557 Allegiant shares per share, an implied $18.89 per share, a 19.8% premium to the $15.77 closing price on January 9, 2026.
Allegiant shareholders would own about 67% of the combined company and Sun Country shareholders about 33%, on a fully diluted basis.
Allegiant expects $140 million in annual synergies within three years of closing and says the deal should be accretive to earnings per share one year after closing.
Termination fees range from $30 million to $52.23 million depending on the circumstances, and the agreement can be terminated if the merger is not completed by January 11, 2027.
ADMA Biologics preliminarily estimated unaudited full-year 2025 total revenue of approximately $510-$511 million, which the company says meets or exceeds its prior guidance. It raised its fiscal 2026 revenue and Adjusted EBITDA guidance, and the figures remain subject to audit and change.
Preliminary unaudited FY 2025 total revenue of approximately $510-$511 million, which the company says meets or exceeds prior guidance
FY 2026 revenue guidance raised to approximately $635 million from $630 million previously
FY 2026 Adjusted EBITDA guidance raised to approximately $360 million from $355 million; FY 2026 Adjusted Net Income guidance reiterated at approximately $255 million
Year-end 2025 cash of approximately $88 million, including an unaudited estimate of approximately $40 million operating cash flow in Q4 2025
Harmony Biosciences said preliminary unaudited WAKIX net product revenue was about $868 million for 2025, up from $714.7 million in 2024, and about $243 million for the fourth quarter, up from $201.3 million a year earlier. It also issued 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion and said it is phasing out its ZYN002 Fragile X program. The figures are unaudited and may change after year-end closing and auditor review.
Preliminary 2025 WAKIX net product revenue of about $868 million, versus $714.7 million in 2024 (about 21% growth)
Q4 2025 preliminary net product revenue of about $243 million, versus $201.3 million in Q4 2024
2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion for the year ending December 31, 2026
ZYN002 Fragile X program being phased out after review of RECONNECT study data; 22q deletion indication no longer pursued
Progyny said on January 12, 2026 that its fourth-quarter 2025 revenue, net income and Adjusted EBITDA are now expected to be slightly above the ranges it gave in November 2025. The company said this excludes any non-cash impacts to net income tied to the previously announced departure of president Michael Sturmer, and that member engagement paced favorably during the quarter. Shareholders get an upward revision to recent guidance, though the filing does not give specific dollar figures.
Fourth-quarter 2025 revenue, net income and Adjusted EBITDA are expected to be slightly above the November 2025 guidance ranges.
The outlook excludes any non-cash impacts to net income from the departure of president Michael Sturmer.
CEO Pete Anevski cited member engagement that paced favorably versus the November guidance.
Management will discuss the updated expectations at the JP Morgan Healthcare Conference on Tuesday, January 13, 2026, at 10:30 a.m. Eastern Time.
Vir Biotechnology said it had approximately $781 million in cash, cash equivalents and investments as of December 31, 2025, an unaudited figure, and that this balance is expected to fund operations into the fourth quarter of 2027, which it links to the Norgine licensing agreement and continued financial discipline. It also released updated Phase 2 SOLSTICE data for its chronic hepatitis delta combination therapy, with 88% of participants evaluated through Week 96 reaching undetectable hepatitis delta virus RNA versus 46% on the antibody alone. The filing contains no full-year revenue or profit figures, which the company expects to report in late February 2026.
Preliminary, unaudited cash, cash equivalents and investments of approximately $781 million as of December 31, 2025; full fourth-quarter and 2025 results expected in late February 2026.
Cash runway extended into the fourth quarter of 2027, tied by the company to the Norgine license for chronic hepatitis delta in Europe, Australia and New Zealand.
SOLSTICE Phase 2: undetectable HDV RNA at Week 96 in 88% (21/24) of combination participants versus 46% (11/24) on tobevibart alone.
Company to present at the J.P. Morgan Healthcare Conference on January 14, 2026, at 3:45 p.m. PT.
BioLife Solutions reported preliminary, unaudited revenue from continuing operations of $96.2 million for 2025, up 29% from 2024, and $24.8 million for the fourth quarter, up 20%. The full-year figure exceeded the top of the guidance range raised in November 2025 ($95.0 million to $96.0 million, adjusted for the evo sale). The company said final results may differ and will provide 2026 guidance with its complete 2025 results in February.
Full-year 2025 revenue from continuing operations: $96.2 million, up from $74.6 million in 2024
Fourth-quarter 2025 revenue: $24.8 million, up from $20.7 million a year earlier
Full-year revenue exceeded the top of the raised guidance range of $95.0 million to $96.0 million
About $1.3 million in biopreservation media revenue was accelerated into the third quarter of 2025 at a customer's request, so it is not in fourth-quarter revenue
TransMedics entered a lease on January 8, 2026 for about 498,286 square feet at 188 Assembly Park Drive in Somerville, Massachusetts, to serve as its new headquarters beginning on or before January 1, 2028, replacing its Andover site. The filing also discloses initial annual base rent of about $23.9 million, an $18 million letter of credit security deposit, and the purchase of two adjacent parcels for $15.0 million each.
Lease covers about 498,286 square feet; base rent initially about $23.9 million per year, rising 2% annually
Lease initial term is 192 months from the Rent Commencement Date, with two ten-year extension options
Security deposit delivered as a letter of credit of about $18 million
On January 8, 2026, the company bought two adjacent Somerville parcels for $15.0 million each, plus related costs
Alkermes furnished a corporate presentation for the J.P. Morgan Healthcare Conference that includes preliminary, unaudited estimated total revenues for 2025. The filing says these figures may change after the company completes its year-end financial statement review, and it gives no prior-year comparison or profit figures.
Presentation states the commercial business generated total revenues above $1.45 billion in 2025.
Revenue figures are preliminary and unaudited and subject to change after the year-end review.
Presentation was made available January 12, 2026, for a J.P. Morgan Healthcare Conference presentation on January 13, 2026.
The planned Avadel acquisition is expected to close in Q1 2026.
Krystal Biotech disclosed preliminary, unaudited 2025 results ahead of its J.P. Morgan Healthcare Conference presentation on January 12, 2026, including VYJUVEK net product revenue and cash of about $955 million as of December 31, 2025. It also gave 2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million. The company said its audit is ongoing and the figures could change, with full 2025 results due in February 2026.
Preliminary Q4 2025 VYJUVEK net product revenue of $106 million to $107 million; full year 2025 of $388 million to $389 million
Cash, cash equivalents and investments of approximately $955 million as of December 31, 2025
2026 combined non-GAAP R&D and SG&A expense guidance of $175 million to $195 million, excluding stock-based compensation
Figures are unaudited and subject to change; full 2025 results to be reported in February 2026
Pegasystems committed on January 7, 2026 to organizational changes, mainly in its Consulting organization, including some role eliminations, to align roles and capacity with an AI-first delivery model. The company expects a charge of approximately $13 million in the fourth quarter of 2025, mostly for cash severance and related benefits.
Changes committed on January 7, 2026, primarily affecting the Consulting organization
Expected charge of approximately $13 million in Q4 2025, mainly cash severance and benefits
Affected employees are being notified; communications expected to be substantially complete in Q1 2026
DexCom reported preliminary, unaudited revenue of about $4.662 billion for fiscal 2025, up 16% from 2024, and about $1.260 billion for the fourth quarter, up 13%. It also gave an initial 2026 total revenue outlook of $5.16-$5.25 billion, growth of about 11-13%, with non-GAAP gross and operating margin targets, and said audited results will follow on February 12, 2026.
Fourth-quarter 2025 revenue of about $1.260 billion, up 13%: U.S. about $892 million (up 11%), international about $368 million (up 18%)
Fiscal 2025 preliminary revenue of about $4.662 billion, up 16%, which the company says exceeded the high end of its guidance
2026 outlook: total revenue of $5.16-$5.25 billion, non-GAAP gross profit margin of about 63-64% and non-GAAP operating margin of about 22-23%
2025 margin guidance reiterated at about 61% non-GAAP gross margin and 20-21% non-GAAP operating margin; audited results due February 12, 2026
Alnylam announced preliminary 2025 global net product revenues of approximately $2,987 million, up 81% from 2024, and full year 2026 combined net product revenue guidance of $4,900 million to $5,300 million. The company also launched a five-year strategy called Alnylam 2030. The figures are unaudited and subject to adjustment until complete results are released in February 2026.
Preliminary fourth quarter 2025 net product revenues were approximately $995 million; full year 2025 was approximately $2,987 million.
2026 combined net product revenue guidance is $4,900 million to $5,300 million, including Total TTR guidance of $4,400 million to $4,700 million.
Results are preliminary and unaudited; complete fourth quarter and full year 2025 results are expected in February 2026.
Management will discuss the results and guidance in a webcast on January 12, 2026 at 9:00 am PT.
FIS completed its acquisition of Global Payments' Issuer Solutions business on January 9, 2026, paying approximately $7.7 billion in cash and exchanging its Worldpay stake for the business. The company says the deal adds a credit issuing processing business and expects it to add $500 million in incremental Adjusted Free Cash Flow in 2026 and $700 million by 2028, though the filing includes no reported financial results for the acquired business.
Closed January 9, 2026; FIS paid approximately $7.7 billion in cash, subject to customary post-closing adjustments.
Issuer Solutions valued at a $13.5 billion enterprise value; Worldpay valued at a $24.25 billion enterprise value.
FIS expects an additional $500 million in Adjusted Free Cash Flow in 2026 and $700 million by 2028.
Financial statements for the acquired business and pro forma information will be filed by amendment within 71 calendar days.
Sotera Health said preliminary full-year 2025 revenue is expected to surpass $1.16 billion, an increase of at least 5.5% year over year, within the guidance it gave with its third-quarter results. The figures are preliminary and remain subject to year-end closing procedures and audit, and the company will release full results and 2026 outlook on February 24, 2026.
Preliminary 2025 revenue expected to surpass $1.16 billion, up at least 5.5% year over year (5.0% on a constant-currency basis)
Revenue approximation is within the guidance given at the third-quarter 2025 earnings release
Figures are unaudited and subject to completion of year-end closing and audit
Full-year 2025 results and 2026 outlook scheduled for February 24, 2026
Global Payments said on January 12, 2026 that it completed its acquisition of Worldpay from FIS and GTCR and sold its Issuer Solutions business to FIS. The filing also issued stock to GTCR, which now holds approximately 15.45% of Global Payments common stock, and set lock-up, standstill and registration terms for those shares. Shareholders face a larger share count and a new ownership stake, and the company said it expects to reduce adjusted net leverage to 3.0x within 18 to 24 months.
Acquisition of Worldpay and divestiture of Issuer Solutions to FIS completed, announced January 12, 2026
Stock Consideration issued to GTCR on January 9, 2026; GTCR now holds approximately 15.45% of outstanding common stock
Lock-up: 35% of GTCR's shares released 12 months after closing, 15% at 15 months, remainder at 18 months
Company expects to reduce adjusted net leverage to 3.0x within 18 to 24 months and plans to invest over $1 billion annually
NeoGenomics said it expects preliminary, unaudited fourth-quarter 2025 revenue of about $190 million, up 11% year over year, and full-year 2025 revenue of about $727 million, up 10%. The company also announced that CFO Jeff Sherman will retire, with Abhishek Jain, formerly CFO of CareDx, becoming Chief Financial Officer on March 2, 2026. The revenue figures are not audited and may change, and the company plans to report full results on its February 2026 earnings call.
Preliminary Q4 2025 revenue of about $190 million, up 11% year over year; full-year 2025 revenue of about $727 million, up 10%
Figures are unaudited, based on management estimates, not reviewed by auditors, and subject to change
Jeff Sherman moves to Executive Vice President, Finance on March 2, 2026, retires April 14, 2026, then serves as special advisor through April 2028
Abhishek Jain to become CFO on March 2, 2026; $520,000 base salary, 60% target bonus, initial equity grant of $2,750,000
Uber said that starting in the first quarter of 2026 it will report Non-GAAP Operating Income, Non-GAAP Net Income and Non-GAAP EPS in place of Adjusted EBITDA, and will switch its segment performance measure to Segment Operating Income. The filing says the change does not restate previously reported GAAP revenue, income from operations, net income or EPS, so it changes how results are presented rather than the reported results themselves.
Non-GAAP Operating Income for the quarter ended September 30, 2025 was $1,675 million, compared with GAAP income from operations of $1,113 million.
Non-GAAP EPS for the quarter ended September 30, 2025 was $0.65, compared with GAAP diluted EPS of $3.11.
The new measures take effect in the first quarter of 2026. Interest income will be shown separately starting with the 10-K for the fiscal year ending December 31, 2025.
The filing provides recast figures for the seven quarters ended September 30, 2025.
Moderna issued preliminary, unaudited 2025 results at the J.P. Morgan Healthcare Conference. Expected revenue of about $1.9 billion is $100 million above the midpoint of its prior $1.6 to $2.0 billion range, and expected GAAP operating expenses were lowered by $200 million. The audit is ongoing and figures could change, and full results are due February 13, 2026.
2025 revenue expected at about $1.9 billion (unaudited), $100 million above the midpoint of the $1.6 to $2.0 billion range from the 3Q25 call
2025 GAAP operating expenses now expected at $5.0 to $5.2 billion (unaudited), an improvement of $200 million
Year-end 2025 cash, cash equivalents and investments expected at about $8.1 billion, including a $0.6 billion draw on a $1.5 billion term loan
2026 framework reiterated: up to 10% revenue growth and about $4.9 billion in GAAP operating expenses
Henry Schein appointed Frederick M. Lowery, currently Executive Vice President and President of Laboratory Products and BioProduction at Thermo Fisher Scientific, as chief executive officer effective March 2, 2026, and expanded its board from 14 to 15 members to seat him. Current CEO Stanley M. Bergman will remain CEO until Lowery starts, then become Chairman of the Board. The filing also amends the company's bylaws to remove the requirement that the board appoint a President.
Lowery's employment agreement sets a base salary of $1,250,000 and a target annual bonus of no less than 150% of base salary for 2026.
Lowery will receive a 2026 equity award with a target grant date fair value of $10,000,000, plus a $2,500,000 sign-on equity award vesting over three years.
Bergman continues as CEO until Lowery begins work, then becomes Chairman of the Board.
The board amended the bylaws effective January 10, 2026, to allow a CEO who is not also President or Chairman.
UnitedHealth said senior management will meet with investors on January 12, 2026 and intends to reaffirm the adjusted 2025 earnings per share expectations it gave on October 28, 2025. The company also warned that full-year 2025 financial closing procedures are not complete, so actual results could change and fall outside the previously disclosed ranges.
Senior management meetings with investors on January 12, 2026
Intent to reaffirm adjusted 2025 EPS expectations first disclosed October 28, 2025
Full-year 2025 closing procedures not yet complete; results could fall outside the ranges
At the J.P. Morgan Healthcare Conference on January 12, 2026, Regeneron disclosed preliminary, unaudited fourth-quarter and full-year 2025 information. The company expects an acquired in-process R&D charge of about $19 million pre-tax, reducing both GAAP and non-GAAP diluted EPS by about $0.14, and about $60 million in matching donations to the Good Days retinal disease fund recorded to SG&A. Shareholders should note that the results are not final and remain subject to closing procedures.
Acquired IPR&D charge of about $19 million pre-tax lowers Q4 2025 GAAP and non-GAAP diluted EPS by about $0.14
Matching program contribution of about $60 million tied to donations to the Good Days Retinal Vascular and Neovascular Disease Fund, recorded to SG&A
Company says results are preliminary and unaudited, and actual results may differ; formal 2026 guidance to come with Q4 2025 earnings
About $3.8 billion returned to shareholders in 2025 and about $1.5 billion remaining under the share repurchase program as of December 31, 2025
Duolingo said Gillian Munson, a board member since 2019 and chair of its Audit, Risk and Compliance Committee, will become chief financial officer effective February 23, 2026, succeeding Matthew Skaruppa, who will move to an advisory role through November 20, 2026. The company also gave preliminary fourth-quarter 2025 metrics, showing DAU growth of approximately 30% year over year and bookings at or slightly above the high end of its guidance range of $329.5 million to $335.5 million.
Gillian Munson becomes CFO effective February 23, 2026, replacing Matthew Skaruppa, who served nearly six years in the role
Munson's base salary is $800,000 and her start-date RSU grant is valued at $14 million, per the filing
Preliminary Q4 2025 DAU growth of approximately 30% year over year
Preliminary Q4 2025 bookings at or slightly above the high end of the $329.5 million to $335.5 million guidance range; the figures remain subject to closing and review procedures
WEX said directors Shikhar Ghosh and Jack VanWoerkom will retire from the board at the 2026 Annual Meeting of Stockholders and will not stand for re-election, and that the board will shrink from twelve seats to ten. David Foss, a director since November, will become Vice Chair and Lead Independent Director, and the company said neither retirement stemmed from a disagreement over operations, policies or practices. The filing includes a press release with a preview of fourth-quarter results, but it gives no figures and says only that the company closed the year with a strong quarter.
Ghosh and VanWoerkom retire effective at the 2026 Annual Meeting of Stockholders
Board seats reduced from 12 to 10 effective at the Annual Meeting
David Foss to become Vice Chair and Lead Independent Director; he joined the board in November
Press release previews fourth-quarter results in general terms only, with no specific figures given
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.